DepoCatalog Reveals the Structural Diversity of Klebsiella Phage Depolymerases and Their Expanding Role in Precision Phage Therapy

-

For decades, bacteriophages have been studied primarily as bacterial predators, but a growing body of work now shows that some of their most sophisticated biological weapons are not the viral particles themselves, but the enzymatic systems they carry on their surface. Among these, phage depolymerases have emerged as one of the most promising tools in modern anti-infective research, especially against encapsulated multidrug-resistant pathogens such as Klebsiella pneumoniae.

A new study published in Nature Communications introduces DepoCatalog, the largest experimentally validated collection of recombinant Klebsiella phage depolymerases assembled to date. The project brings together 129 distinct enzymes capable of degrading bacterial capsules across 75 Klebsiella capsule types, providing an unprecedented structural and functional overview of how bacteriophages adapt to the remarkable diversity of bacterial polysaccharides.

The Phage Therapy (c)

Klebsiella pneumoniae remains one of the most clinically problematic Gram-negative pathogens worldwide. Its thick capsular polysaccharide layer protects the bacterium from immune recognition, phagocytosis, complement-mediated killing and, in many cases, antibiotic penetration. This capsule also acts as the first physical barrier encountered by bacteriophages during infection. To overcome this obstacle, many phages encode depolymerases, specialized receptor-binding proteins that enzymatically cleave the capsule and expose the bacterial surface beneath.

The new catalog was developed through a large-scale comparative effort combining recombinant protein production, capsule degradation assays, structural prediction using AlphaFold3, and computational domain analysis. The researchers analyzed depolymerases originating from podoviruses, siphoviruses, myoviruses, jumbo phages and prophages, revealing that capsule-targeting enzymes are far more structurally diverse than previously assumed.

One of the most striking conclusions of the study is that depolymerases sharing similar biological activity may possess radically different sequences and structural organizations. In several cases, unrelated phages evolved distinct enzymes capable of targeting the same Klebsiella capsule type. This suggests that convergent evolution plays a major role in shaping phage adaptation toward bacterial glycans. At the same time, certain depolymerases displayed broad substrate activity, recognizing multiple capsule types rather than a single serotype.

The authors propose a new classification system dividing depolymerases into five major structural classes and fourteen subclasses. Most enzymes retained the classical beta-helical architecture characteristic of phage tail spike proteins, yet many displayed additional insertion domains, elongated tail-fiber regions or highly variable C-terminal modules. According to the structural analyses, the C-terminal region appears to be one of the main determinants governing capsule specificity and host-range expansion. Even subtle conformational changes in this domain were associated with major shifts in glycan recognition.

This observation carries important implications for synthetic biology and engineered phage therapeutics. If capsule specificity can be altered through targeted modifications of receptor-binding domains, future phage-derived therapeutics may become programmable. Instead of isolating entirely new phages for every resistant strain, researchers could potentially redesign depolymerases to recognize emerging capsule variants.

The study also highlights intriguing evolutionary differences between phage families. Small podoviruses carrying only one or two receptor-binding proteins frequently exhibited broader depolymerase specificity, while jumbo phages relied on large repertoires of highly specialized enzymes. The authors suggest that these represent two distinct evolutionary strategies for overcoming bacterial capsule diversity.

Beyond phage therapy itself, depolymerases are increasingly viewed as stand-alone anti-virulence agents. By degrading the bacterial capsule without directly killing the cell, these enzymes can sensitize pathogens to immune clearance, improve antibiotic penetration, disrupt biofilms and expose bacteria to secondary phage infection. Experimental animal models have already demonstrated improved survival in severe Klebsiella infections following depolymerase treatment.

Importantly, the authors also emphasize the diagnostic value of these proteins. Because many depolymerases recognize highly specific capsular structures, they could eventually become rapid tools for Klebsiella serotyping in clinical microbiology laboratories. This would represent a major advantage in hospital surveillance, outbreak monitoring and personalized phage therapy selection.

To support future research, the team created DepoCat, an open-access interactive database that allows users to explore depolymerase structures, specificity profiles and predicted domains through integrated 3D visualization tools. The platform may become an important resource for researchers attempting to predict phage-host interactions or design engineered receptor-binding proteins for therapeutic applications.

Although the current catalog covers only a fraction of the more than 160 known Klebsiella capsule loci, it already represents one of the most comprehensive experimental resources available in the field of phage glycobiology. As more depolymerases are discovered and structurally characterized, datasets like DepoCatalog could help bridge one of the biggest challenges in phage therapy: predicting which phage-derived proteins will work against which bacterial capsule types.

In many ways, this work reflects a broader transition occurring in phage research. The field is no longer focused solely on whole-phage therapeutics, but increasingly on the molecular mechanisms bacteriophages evolved over billions of years of conflict with bacteria. Depolymerases may ultimately become some of the most clinically valuable products of that evolutionary arms race.

Source: https://doi.org/10.1038/s41467-026-73570-7

Comments

Post a Comment

Most Consulted Articles

History Part 12 : Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s)

-
Image
Post-War Stagnation and Phage Therapy’s Marginalization in the West (1945–1980s) The period following World War II marked a decisive turning point in the trajectory of phage therapy in Western medicine. Despite the promising results bacteriophages had demonstrated prior to the war as potential antibacterial agents, the decades after 1945 saw a dramatic decline in interest, funding, and scientific engagement with phage therapy in the United States and much of Western Europe. This marginalization can be attributed to a confluence of scientific, sociopolitical, and economic factors that reshaped the landscape of infectious disease treatment and research. Artistic View One of the key contributors to this decline was the overwhelming optimism surrounding the newly discovered class of antibiotics. The post-war pharmaceutical revolution brought forward a series of broad-spectrum antibiotics such as streptomycin, tetracycline, and chloramphenicol, which were viewed as miracle drugs capable o...
Read more

The Phage Therapy in the spotlight !

-
Image
Bacteriophages: Ancient Predators and the Next Frontier in Medicine In the animated documentary The Deadliest Being on Planet Earth , the Kurzgesagt team delves into the world of bacteriophages—viruses that prey exclusively on bacteria. With vibrant visuals and precise narration, the video introduces viewers to an invisible ecosystem where microscopic hunters orchestrate life-and-death dramas that shape the biosphere. These entities, though virtually unknown to the general public, may soon become central to the future of medicine. At the heart of the video lies a paradox: bacteriophages (or "phages") are among the most abundant biological entities on Earth—outnumbering all other organisms combined—yet their therapeutic potential has been largely sidelined in the antibiotic era. The video outlines the historical trajectory of phage research, spotlighting Félix d’Hérelle’s early 20th-century work and the rise of phage therapy, only to show how it was later eclipsed by the dis...
Read more

Groundbreaking achievement : Phagos raises €25m to end bacterial disease

-
Image
 Phagos raises €25m to end bacterial disease  The company holds the first authorization to market personalized veterinary phage-based treatments on EU soil  ● Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology and AI, Phagos offers the first phage-based drugs for veterinary use, a market worth tens of billions of dollars. The company plans to expand further as phage therapy becomes accepted in human health.                              ● The funding round was co-led by CapAgro, Hoxton Ventures, CapHorn, and Demeter alongside Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, and Station F.  ● Objectives: deploy veterinary treatments in the field, develop the next generation of pat...
Read more

EMA : Guideline on quality aspects of phage therapy medicinal products

-
Image
The European Medicines Agency Publishes Draft Guideline on Quality Aspects of Phage Therapy Medicinal Products: A Landmark in the Regulation of Bacteriophage Therapeutics Introduction On 16 October 2025 , the European Medicines Agency (EMA) , through its Committee for Medicinal Products for Human Use (CHMP) and the Biologics Working Party (BWP) , adopted for public consultation the draft Guideline on Quality Aspects of Phage Therapy Medicinal Products (EMA/CHMP/BWP/1/2024) . This 15-page document represents the first comprehensive regulatory framework in the European Union specifically addressing the quality, manufacturing, and control requirements for bacteriophage-based medicinal products intended for human use. The release of this draft guideline is a significant milestone in the development of phage therapy as a legitimate, standardised, and potentially widely accessible treatment modality for bacterial infections, particularly in the context of the global antimicrobial resi...
Read more

EUCAST creates a Subcommittee on Phage susceptibility testing

-
Image
Subcommittee on Phage susceptibility testing Lytic bacteriophages, or phages, are viruses that infect and kill bacteria. Phage therapy is emerging as a promising adjuvant to traditional antimicrobials for combatting difficult-to-treat bacterial infections. However, implementation of phage-based treatments requires standardized methods for testing their efficacy to select the optimal therapeutic phages. To address this, EUCAST has established the EUCAST Phage Susceptibility Testing (PST) Subcommittee Remit of the PST Subcommittee : - Developing  standardized reference methods  to ensure uniform and reproducible  in vitro  phage susceptibility testing across laboratories worldwide, - Establishing  criteria for interpretation of PST results , providing clinicians and researchers with evidence-based guidelines to assess phage efficacy and monitor phage activity. - Promoting  quality assurance  by implementing stringent  quality control  measures ...
Read more